Clinical trial register · Germany

Clinical Trials in Würzburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 20 Oct 2026, 03:18 UTC

5062

Studies in scope

all four open statuses

2873

Recruiting now

open to new participants

988

Lead sponsors

across recruiting studies

Top sites

Berlin 1586 Hamburg 889 Essen 766 Dresden 716 Heidelberg 627

Trials with a site in Würzburg

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Not yet open

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562Systemic Sclerosis

DrugsZola-cel·Nintedanib·Tocilizumab·Fludarabine

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg

2027-02-03

Not yet open

Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care

NCT07699640Testicular Cancer, Testicular Germ Cell Tumor

Heinrich-Heine University, Duesseldorf

Not applicable

171

Ulm, Würzburg, Hamburg, Marburg, Cologne, Düsseldorf, Wuppertal, Dresden

2027-01

Not yet open

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188Relapsed or Refractory Multiple Myeloma

DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide

AbbVie

Phase 3

520

Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne

2026-11-30

Not yet open

Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial

NCT07840456Carcinoma, Squamous Cell of Head and Neck HNSCC

DrugsRuxolitinib·Pembrolizumab

University Hospital, Basel, Switzerland

Phase 2

Würzburg, Greifswald, Cologne, Hagen, Hamburg

2026-11

Not yet open

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies

Bristol-Myers Squibb

Phase 1

Berlin, Erlangen, Magdeburg, Würzburg

2026-10-30

Not yet open

Impact of Iron Supplementation During Pregnancy

NCT07814378Anemia, Iron Deficiency Anaemia in Childbirth, Pregnancy

DrugIron

Johann Wolfgang Goethe University Hospital

Observational

800

Frankfurt, Würzburg

2026-10-01

Not yet open

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NCT07178730Breast Cancer, Triple-negative Breast Cancer

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Women's Cancer Study Group GmbH

Phase 3

765

Heilbronn, Weinheim, Augsburg, München, Regensburg, Würzburg, Cottbus, Bad Nauheim

2026-08-30

Recruiting

Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)

NCT07739914Liver Allograft, Liver Diseases, Liver Transplantation

DrugsCyclosporine·Tacrolimus·Everolimus

Hannover Medical School

Phase 3

150

Heidelberg, Tübingen, Regensburg, Würzburg, Hamburg, Hanover, Rostock, Aachen

2026-08-19

Recruiting

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680Solid Tumors

DrugsNavlimetostat·Pumitamig·Temozolomide·Cetuximab

Bristol-Myers Squibb

Phase 2

260

Mainz, Hamburg, Heidelberg, Leipzig, München, Würzburg

2026-07-27

Recruiting

Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

NCT07649681Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)

Wuerzburg University Hospital

Not applicable

198

Augsburg, Erlangen, München, Regensburg, Würzburg

2026-07-24

Recruiting

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

NCT07690436Transthyretin Amyloid Cardiomyopathy

AstraZeneca

Observational

500

Berlin, Essen, Frankfurt am Main, Würzburg

2026-07-08

Recruiting

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

NCT07600476Cutaneous Melanoma, Mucosal Melanoma, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin

Kupando GmbH

Phase 1

Munich, Würzburg, Münster

2026-07-03

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241Small Cell Lung Cancer

DrugsABBV-706·Amrubicin·Lurbinectedin·Topotecan

AbbVie

Phase 3

531

Würzburg, Kassel, Cologne

2026-07-02

Recruiting

BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs

NCT07360158Tachyarrhythmia, Heart Failure

Biotronik SE & Co. KG

Observational

151

Würzburg, Gera

2026-06-22

Recruiting

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

NCT07583563Acromegaly

Camurus AB

Observational

200

Aachen, Leipzig, Magdeburg, München, Würzburg

2026-06-05

Recruiting

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)

Novartis Pharmaceuticals

Phase 3

300

Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin

2026-06-03

Recruiting

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

NCT07387198Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

135

Heidelberg, Mannheim, Tübingen, Regensburg, Würzburg, Hamburg, Frankfurt am Main, Bielefeld

2026-05-29

Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797Relapsed or Refractory Large B-cell Lymphoma

DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 3

550

Würzburg

2026-05-22

Recruiting

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214Polymyalgia Rheumatica

DrugSarilumab

Sanofi

Phase 4

300

Berlin, Freiburg im Breisgau, Hamburg, Herne, Neubrandenburg, Würzburg

2026-05-12

Recruiting

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

NCT07242352Breast Cancer, HR+/HER2- Breast Cancer

DrugElacestrant

Women's Cancer Study Group GmbH

Phase 3

1,520

Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg

2026-04-29

Recruiting

Investigating the Mechanisms of Decision-Making Using Non-Invasive Brain Stimulation

NCT07749378Young Healthy Adults

Wuerzburg University Hospital

Not applicable

Würzburg

2026-04-27

Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

NCT07531095Small Cell Lung Cancer

DrugsZL-1310·Tarlatamab·Durvalumab

Amgen

Phase 1

160

Dresden, Würzburg

2026-04-21

Recruiting

Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons

NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer

University of Regensburg

Not applicable

384

Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne

2026-04-21

Recruiting

Exploratory Investigation of the Acceptance and Utility of 14-day Trial Periods and Application-related Outcome Measurement (AbEM) Within the Routine Prescription of the DiGA Axia.

NCT07561255Spondylitis, Ankylosing, Mobile Phone Use

Wuerzburg University Hospital

Not applicable

200

Würzburg, Erlangen, Hamburg, Hattingen, Marburg, Nuremberg

2026-04-10

Recruiting

Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta

NCT07366086Osteogenesis Imperfecta

Amgen

Phase 3

Cologne, Würzburg

2026-03-18

Not yet open

Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity

NCT07417683Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH

Trans-Duodenal Concepts GmbH

Not applicable

126

Mannheim, Bamberg, Würzburg, Bochum, Dresden, Leipzig, Berlin

2026-03

Recruiting

A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)

NCT07306559Advanced Relapsed or Refractory Germ Cell Tumours, Advanced Relapsed or Refractory Endometrial Cancer, Advanced Relapsed or Refractory Ovarian Cancer

Boehringer Ingelheim

Phase 1

187

München, Würzburg

2026-02-27

Recruiting

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083Focal Segmental Glomerulosclerosis

DrugApecotrep

Boehringer Ingelheim

Phase 3

286

Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg

2026-02-16

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Düsseldorf, Heidelberg, Jena, Würzburg

2026-02-04

Recruiting

Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region

NCT07290712PICS, PICS-F

Medical University of Vienna

Observational

5,000

Augsburg, Würzburg, Berlin

2026-02-04

Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

NCT07358078Transthyretin Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals

Observational

2,000

Heidelberg, Munich, Münster, Würzburg

2026-01-09

Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD0120

AstraZeneca

Phase 1

Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg

2026-01-09

Recruiting

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562Multiple Myeloma

DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

1,000

Greifswald, Lübeck, Würzburg

2025-12-23

Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

DrugsEmpasiprubart·Efgartigimod

argenx

Phase 2

Berlin, Göttingen, Würzburg

2025-12-19

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis

DrugsEmpasiprubart·Efgartigimod

argenx

Observational

Berlin, Göttingen, Würzburg

2025-12-19

Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 3

150

Munich, Würzburg

2025-12-11

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg

2025-12-10

Recruiting

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

NCT07224373Multiple Sclerosis

AstraZeneca

Phase 1

Leipzig, Magdeburg, Würzburg

2025-12-09

Recruiting

Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management

NCT07780916Glaucoma, Glaucoma Patient, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Glaucoma Following Surgery

Wuerzburg University Hospital

Observational

200

Würzburg

2025-12-03

Recruiting

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

NCT06847542Neovascular Age-related Macular Degeneration

DrugRanibizumab

Hoffmann-La Roche

Phase 3

250

Chemnitz, Düsseldorf, Göttingen, Hanover, Rostock, Würzburg

2025-11-27

Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625Acromegaly

Debiopharm International SA

Phase 3

119

Berlin, Munich, Würzburg

2025-11-26

Recruiting

Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders

NCT07040189Multiple Myeloma, GI Cancer, Taste Disorders

Wuerzburg University Hospital

Not applicable

Munich, Regensburg, Würzburg

2025-11-25

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

München, Münster, Oldenburg, Regensburg, Würzburg

2025-11-24

Recruiting

Giant Cell Arteritis - Ways to Precision Medicine

NCT07084480Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)

Wuerzburg University Hospital

Observational

400

Würzburg

2025-11-14

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

Bochum, Bramsche, Frankfurt, Kiel, Mainz, Münster, Würzburg

2025-11-06

Recruiting

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

NCT06243731Cytomegalovirus (CMV), Kidney Disease, Kidney Failure

Takeda

Observational

Würzburg, Leipzig

2025-11-03

Recruiting

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)

DrugAvacincaptad Pegol

ONL Therapeutics

Phase 2

324

Ahaus, Bonn, Düsseldorf, Frankfurt am Main, Marburg, Würzburg

2025-10-28

Recruiting

Existential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU)

NCT07312760Advanced Cancer, Various, NOS

Universitätsklinikum Hamburg-Eppendorf

Not applicable

160

Düsseldorf, Hamburg, Würzburg

2025-10-24

Recruiting

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics, Inc.

Observational

140

Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg

2025-10-17

Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

NCT07246863Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsVisugromab RDE·Visugromab·Opdivo·Docetaxel

CatalYm GmbH

Phase 2

131

Esslingen am Neckar, Heidelberg, Würzburg, Bielefeld, Essen, Moers

2025-10-07

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Jerichow

2025-10-01

Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275Primary Membranous Nephropathy

DrugsPovetacicept·Tacrolimus

Vertex Pharmaceuticals Incorporated

Phase 2/3

176

Allemagne, Leipzig, Würzburg

2025-09-30

Recruiting

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

NCT07179640Hypophosphatasia (HPP)

Alesta Therapeutics

Phase 1/2

120

Würzburg

2025-09-30

Recruiting

International Study of the SING IMT™ Prosthesis in Pseudophakic patiEnts With Stable Moderate to Profound Bilateral Central vIsion Impairment Due to adVancEd AMD / PERSPECTIVE Study

NCT07164378Age - Related Macular Degeneration (AMD)

VisionCare, Inc.

Not applicable

Hamburg, Sulzbach, Trier, Würzburg

2025-09-23

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

München, Frankfurt am Main, Halle, Cologne, Würzburg

2025-09-09

Active, closed

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

212

Berlin, Düsseldorf, Kaiserslautern, München, Würzburg

2025-08-07

Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

NCT07098988Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor

DrugsPemetrexed /m^2·Carboplatin (AUC 5)·Visugromab·Keytruda

CatalYm GmbH

Phase 2

107

Heidelberg, Würzburg, Bielefeld, Essen, Moers, Großhansdorf

2025-08-01

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Heidelberg, Munich, Würzburg, Hamburg

2025-07-23

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg

2025-07-21

Recruiting

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT06779630Coronary Artery Disease

Teleflex

Not applicable

150

Mannheim, Fürth, Würzburg, Bad Segeberg

2025-07-18

Recruiting

Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.

NCT06576583Patellofemoral Osteoarthritis

DrugN-Tec

University Hospital, Basel, Switzerland

Phase 2

150

Berlin, Würzburg

2025-07-15

Active, closed

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

NCT06649695AL Amyloidosis

DrugTeclistamab

European Myeloma Network B.V.

Phase 2

Essen, Heidelberg, Würzburg

2025-07-02

Recruiting

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)

NCT07067437Breast Neoplasms

National Institute of Oncology, Hungary

Not applicable

250

Bremerhaven, Erlangen, Lübeck, Offenbach, Würzburg

2025-07-01

By invitation

NCT06931132Cancer Survivors

Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)

Not applicable

172

Stuttgart, Würzburg

2025-06-05

Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490Multiple Sclerosis Spasticity

DrugIrafamdastat

Celgene

Phase 2

200

Würzburg, Kassel, Bochum, Münster, Siegen, Meisenheim, Jena, Bielefeld

2025-06-05

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Bochum, Goettigen, Magdeburg, Würzburg

2025-05-27

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Mannheim, Tübingen, Würzburg, Erlangen, Martinsried, Haus, Buxtehude, Minden

2025-05-22

Recruiting

Training Physicians to Differentiate the Paris Classification Using Artificial Colon Polyp Images

NCT06550908Colonic Polyp, Colon Adenoma

Wuerzburg University Hospital

Not applicable

Würzburg

2025-04-15

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2

594

Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel

2025-04-11

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

565

Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin

2025-03-20

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg

2025-03-18

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Frankfurt, Hanover, Münster, Ulm, Würzburg

2025-03-14

Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623Non Small Cell Lung Carcinoma, c-MET

DrugsBudigalimab·Telisotuzumab Adizutecan·Pemetrexed·Cisplatin

AbbVie

Phase 1/2

252

Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein

2025-03-06

Not yet open

Implementation of the International Classification of Functioning, Disability and Health Model in Paediatric Cochlear Implant Recipients

NCT06841900Cochlear Impant Children

University Hospital, Antwerp

Observational

120

Würzburg

2025-03

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Berlin, Homburg, Kiel, Würzburg

2025-02-26

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834347Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

231

Berlin, Frankfurt, Hamburg, Landsberg, Münster, Tübingen, Wiesbaden, Würzburg

2025-02-12

Recruiting

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

NCT06624670Pyoderma Gangrenosum

DrugsSpesolimab·Prednisolone·Prednisone

LEO Pharma

Phase 3

Berlin, Düsseldorf, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg

2025-02-05

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Cologne, Homburg, Kiel, Mainz, München, Würzburg

2025-01-30

Recruiting

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

NCT06657157Urothelial Cancer

Comprehensive Cancer Center Munich (CCCM)

Observational

Augsburg, Munich, Würzburg

2025-01-22

Recruiting

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

NCT07491601Postoperative Hypoparathyroidism, Postsurgical Hypoparathyroidism, Hypoparathyroidism Post-surgical

DrugCalcium

Nicolas Schlegel

Not applicable

336

Würzburg

2025-01-08

Recruiting

Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups

NCT07212075Diabetes (DM), Diabete Mellitus, Diabete Type 1, Diabete Type 2

Forschungsinstitut der Diabetes Akademie Mergentheim

Observational

1,809

Bad Mergentheim, Würzburg

2025-01-01

Recruiting

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction

Cytokinetics

Phase 3

1,800

Heidelberg, München, Würzburg, Hamburg, Erfurt, Jena, Mainz, Bad Nauheim

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Essen, Göttingen, Lübeck, Münster, Potsdam, Würzburg

2024-12-18

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Dresden, Munich, Schwerin, Würzburg

2024-12-17

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Berlin, Chemnitz, Essen, Jena, Würzburg

2024-11-27

Recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565Myasthenia Gravis

DrugEfgartigimod

argenx

Observational

680

Altenburg, Bochum, Göppingen, Göttingen, Gummersbach, Jena, Würzburg

2024-11-04

Active, closed

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor

Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab

Eli Lilly and Company

Phase 1

750

Frankfurt, Hamburg, Heilbronn, Würzburg

2024-10-21

Active, closed

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481Amyotrophic Lateral Sclerosis (ALS)

DrugVHB937

Novartis Pharmaceuticals

Phase 2

251

Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster

2024-10-17

Active, closed

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06470048Diffuse Cutaneous Systemic Sclerosis

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

201

Würzburg, Jena, Berlin

2024-10-09

Recruiting

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636X-linked Hypophosphatemia

Kyowa Kirin Co., Ltd.

Phase 1/2

Hamburg, Würzburg

2024-10-09

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

Regensburg, Würzburg

2024-10-07

Recruiting

ColoReg: A Register for Gastrointestinal Endoscopy Reports and Examination Videos

NCT06920680Colorectal Cancer, Colonoscopy, Polypectomy

Wuerzburg University Hospital

Observational

1,834

Stuttgart, Würzburg

2024-10-01

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Göttingen, München, Ulm, Würzburg

2024-09-18

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum

2024-09-18

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Essen, Heidelberg, Würzburg

2024-09-17

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

NCT06572384Lung Diseases, Interstitial

DrugBelimumab

GlaxoSmithKline

Phase 3

440

Essen, Minden, Mainz, Würzburg

2024-09-11

Recruiting

Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer

NCT06517719Metastatic Castration Resistant Prostate Cancer

Novartis Pharmaceuticals

Observational

500

Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen

2024-09-04

Recruiting

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

NCT06274801Pulmonary Arterial Hypertension

Gossamer Bio USA, Inc.

Phase 3

330

Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg

2024-09-03

Recruiting

Liquid Biopsy Under PSMA Radioligand Therapy

NCT07118436Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer

Wuerzburg University Hospital

Observational

100

Augsburg, München, Würzburg

2024-09-01

Active, closed

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

NCT06577025Multiple Myeloma

DrugsCilta-cel·Talquetamab·Teclistamab·Bortezomib

Janssen Research & Development, LLC

Phase 2

Heidelberg, Tübingen, Würzburg

2024-08-20

Recruiting

Rapid Point-of-care Bacteriuria and Microbial Susceptibility for Women With Suspected Uncomplicated Urinary Tract Infections: Diagnostic Accuracy in General Practice.

NCT06625268Urinary Tract Infection (Diagnosis)

Wuerzburg University Hospital

Observational

200

Würzburg, Jena

2024-08-01

By invitation

Decrease Caregiving Fatigue in Group Leaders of a Support Group for Women After Cancer

NCT06937606Caregiver Burden

Wuerzburg University Hospital

Not applicable

Würzburg

2024-07-31

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen

2024-07-31

Recruiting

Clinical Performance of the New Plasma Filter PX2 in TPE Treatments

NCT06382675Autoimmune Diseases

Fresenius Medical Care Deutschland GmbH

Not applicable

Aschaffenburg, Munich, Braunschweig, Paderborn, Berlin, Ulm, Würzburg

2024-07-18

Not yet open

Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

NCT03865277Head and Neck Squamous Cell Carcinoma

Technische Universität Dresden

Phase 2

276

Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München

2024-07-01

Active, closed

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312Polymyalgia Rheumatica

DrugSecukinumab

Novartis Pharmaceuticals

Phase 3

162

Freiburg im Breisgau, Würzburg, Berlin, Herne

2024-06-28

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Würzburg, Frankfurt am Main, Hanover, Aachen, Cologne, Mainz, Homburg, Berlin

2024-06-25

Active, closed

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643Parkinson Disease

DrugAAV2-GDNF gene therapy

AskBio Inc

Phase 2

127

Berlin, Marburg, Tübingen, Würzburg

2024-06-11

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Chemnitz, Hamburg, Heidelberg, Würzburg

2024-06-07

Recruiting

Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.

NCT06163573Patellofemoral Osteoarthritis

DrugsN-Tec·Platelet rich plasma

University Hospital, Basel, Switzerland

Phase 2

Freiburg im Breisgau, Würzburg

2024-06-06

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg

2024-06-05

Recruiting

Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis

NCT06492200Arthritis, Rheumatoid

Wuerzburg University Hospital

Not applicable

Würzburg

2024-06-01

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Essen, Heidelberg, Würzburg

2024-05-29

Active, closed

Analysis of TPE Treatments With multiFiltratePRO

NCT06272084Autoimmune Diseases

Fresenius Medical Care Deutschland GmbH

Observational

Aschaffenburg, Würzburg, Berlin

2024-05-22

Recruiting

Corheart 6 LVAS Study

NCT05876000Refractory Heart Failure

Shenzhen Core Medical Technology CO.,LTD.

Not applicable

Bad Oeynhausen, Berlin, Bremen, Hamburg, Heidelberg, Leipzig, Würzburg

2024-05-14

Recruiting

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

NCT06508775Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma

DrugsMB-CART19.1·Zamtocabtagene autoleucel

Miltenyi Biomedicine GmbH

Not applicable

Berlin, Cologne, Erlangen, Göttingen, Münster, Tübingen, Würzburg

2024-05-05

Active, closed

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551Osteogenesis Imperfecta

DrugRomosozumab

Amgen

Phase 3

111

Cologne, Würzburg

2024-04-22

Recruiting

European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV

DrugsKeytruda·Pembrolizumab

University of Leipzig

Phase 2

140

Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig

2024-04-17

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Berlin, Bochum, Würzburg

2024-04-16

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Berlin, Cologne, Großhansdorf, Moers, Würzburg

2024-02-22

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Essen, Göttingen, Würzburg

2024-02-20

Active, closed

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

NCT06260709Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 2

Heidelberg, München, Münster, Würzburg

2024-02-20

Active, closed

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy

NCT05990738Small Cell Lung Carcinoma (SCLC)

DrugsObrixtamig·Topotecan

Boehringer Ingelheim

Phase 1

Dresden, Erlangen, Heidelberg, Mainz, Würzburg

2024-02-14

Recruiting

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

NCT06553625Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders

Boston Scientific Corporation

Observational

200

Cologne, Düsseldorf, Würzburg

2024-01-29

Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)

DrugsAZD3470·Keytruda·Pembrolizumab

AstraZeneca

Phase 1/2

161

Berlin, Cologne, Erlangen, Würzburg

2024-01-23

Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06153251Relapsed and/or Refractory Multiple Myeloma

DrugsFludara·Cytoxan·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

187

Cologne, Heidelberg, Würzburg

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg

2024-01-22

Recruiting

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)

NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

AvenCell Europe GmbH

Phase 1

Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen

2024-01-03

Active, closed

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281Hypophosphatasia

DrugALXN1850

Alexion Pharmaceuticals, Inc.

Phase 3

124

Bad Reichenhall, Berlin, Bonn, Hamburg, Würzburg

2024-01-03

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

Esslingen am Neckar, Würzburg, Oldenburg, Berlin, Cologne, Dresden, Gauting, Immenhausen

2023-12-21

Recruiting

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318Relapsed/Refractory Multiple Myeloma (RRMM)

Janssen-Cilag Ltd.

Observational

900

Chemnitz, Dresden, Hamburg, Hanover, Heidelberg, Nuremberg, Würzburg

2023-12-18

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Berlin, Essen, Heidelberg, Würzburg

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Stuttgart, Würzburg, Mutlangen, Frankfurt am Main, Mainz, Dresden, Berlin, Kiel

2023-12-12

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg

2023-12-05

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Würzburg, Frankfurt am Main, Mainz, Homburg, Leipzig, Lübeck, Berlin

2023-12-01

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Essen, Giessen, Hanover, Potsdam, Würzburg

2023-11-29

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353Cytomegalovirus (CMV)

DrugMaribavir

Takeda

Phase 3

Würzburg, Münster, Jena, Hamburg, Hanover

2023-11-13

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover

2023-10-27

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsAdagrasib·Cabozantinib

Kura Oncology, Inc.

Phase 1

300

Berlin, Ulm, Würzburg

2023-10-18

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Cologne, Hamburg, Leipzig, Tübingen, Würzburg

2023-10-10

Recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

NCT05755386IC-MPGN

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

106

Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover

2023-10-02

Active, closed

German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

NCT06095713Fabry Disease

DrugPegunigalsidase-alfa

Universität Münster

Observational

Berlin, Cologne, Hamburg, Hanover, Mainz, Müllheim, Münster, Würzburg

2023-10-01

Active, closed

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis

DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

270

Würzburg, Cologne, Leipzig, Magdeburg, Berlin, Düsseldorf, Erlangen

2023-09-13

Active, closed

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941Sjögren's Syndrome

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

774

Munich, Berlin, Freiburg im Breisgau, Hamburg, Tübingen, Würzburg

2023-09-11

Active, closed

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

NCT05884398Metastatic Castrate-sensitive Prostate Cancer

DrugApalutamide

Janssen Research & Development, LLC

Phase 3

420

Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg

2023-08-31

Recruiting

Auricular Acupuncture in Patients With Advanced Cancer: a Randomized Clinical Trial.

NCT05762250Fatigue, Pain, Depression, Advanced Tumour Diseases

University Hospital Tuebingen

Not applicable

125

Stuttgart, Würzburg

2023-08-13

Recruiting

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

NCT05958121Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer

Immatics Biotechnologies GmbH

Phase 1/2

400

Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Nuremberg, Regensburg, Würzburg

2023-08-09

Active, closed

Performance of the SPIRION Laryngeal Pacemaker in BVFP Patients Without Glottal Enlargement

NCT06007170Bilateral Vocal Cord Paralysis

MED-EL Elektromedizinische Geräte GesmbH

Not applicable

Stuttgart, Würzburg, Gera, Berlin

2023-07-27

Recruiting

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

NCT05332561Early-stage Breast Cancer

DrugsIpatasertib·Phesgo·Inavolisib·Sacituzumab Govitecan

German Cancer Research Center

Phase 2

240

Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin

2023-06-29

Active, closed

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

NCT05889182Hidradenitis Suppurativa

DrugUpadacitinib

AbbVie

Phase 3

1,328

Freiburg im Breisgau, Erlangen, Regensburg, Würzburg, Frankfurt am Main, Bad Bentheim, Bramsche, Düsseldorf

2023-06-21

Recruiting

Trabeculopuncture as Predictive Test for the Success of Ab Interno Trabeculectomy

NCT06523751Open Angle Glaucoma, Pseudoexfoliation Glaucoma

Wuerzburg University Hospital

Not applicable

Würzburg

2023-06-13

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

DrugVenetoclax

AbbVie

Phase 1

135

Ulm, Würzburg, Rostock, Homburg, Berlin, Hamburg

2023-06-09

Active, closed

Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism

NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Alexion Pharmaceuticals, Inc.

Phase 3

165

Dresden, Munich, Würzburg

2023-06-07

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Berlin, Cologne, Dresden, Essen, Gauting, Großhansdorf, Stuttgart, Würzburg

2023-05-31

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel

2023-05-17

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

NCT05844046Hepatocellular Carcinoma

Enrico De Toni

Phase 2

Munich, Würzburg

2023-04-06

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Berlin, Hamburg, Herne, Planegg, Würzburg

2023-04-05

Active, closed

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

NCT05794906Biochemically Recurrent Prostate Cancer

DrugDarolutamide

Bayer

Phase 3

985

Mannheim, Nürtingen, Stuttgart, Würzburg, Frankfurt am Main, Braunschweig, Göttingen, Aachen

2023-04-03

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma

DrugsLifileucel·Pembrolizumab

Iovance Biotherapeutics, Inc.

Phase 3

670

Berlin, Würzburg, Dresden, Hamburg, Lübeck, Munich

2023-03-30

Recruiting

The DefiPace Study

NCT04804748Post-operative Atrial Fibrillation POAF

Institut für Pharmakologie und Präventive Medizin

Observational

450

Erlangen, Nuremberg, Würzburg, Oldenburg, Dresden, Freiburg im Breisgau, Hanover, Jena

2023-03-28

Active, closed

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma

DrugsTovorafenib·Carboplatin

Day One Biopharmaceuticals, Inc.

Phase 3

418

Freiburg im Breisgau, Augsburg, Erlangen, Würzburg, Frankfurt am Main, Hanover, Essen, Leipzig

2023-02-27

Active, closed

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968Carcinoma, Non-Small-Cell Lung

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Mannheim, Kempten (Allgäu), Würzburg, Koblenz, Halle, Berlin

2023-02-06

By invitation

A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

NCT05718570Adult Growth Hormone Deficiency

DrugSomapacitan

Novo Nordisk A/S

Observational

400

Aachen, Frankfurt am Main, Halle, Mainz, München, Oldenburg, Würzburg

2023-02-03

Recruiting

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

NCT05665140Newly Diagnosed Multiple Myeloma

DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide

University Hopsital Schleswig Holstein Campus Lübeck

Phase 2/3

100

Berlin, Bielefeld, Hamburg, Lübeck, Münster, Würzburg

2023-02-03

Recruiting

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06311708Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics

Observational

200

Münster, Würzburg

2023-01-31

Recruiting

Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer

NCT05652348Gastric Cancer, Colon Cancer, Peritoneal Carcinomatosis

Technische Universität Dresden

Observational

Berlin, Cologne, Dresden, Ulm, Würzburg

2022-12-08

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Cologne, Heidelberg, Homburg, Münster, Würzburg

2022-11-30

Active, closed

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

DrugsAsciminib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 3

568

Freiburg im Breisgau, Mannheim, Munich, Würzburg, Frankfurt am Main, Marburg, Paderborn, Velbert

2022-11-21

Active, closed

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Observational

6,000

Erlangen, Trier, Würzburg, Cottbus, Potsdam, Frankfurt am Main, Hanover, Greifswald

2022-11-21

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Berlin, Düsseldorf, München, Würzburg

2022-11-21

Recruiting

Non-invasive Detection of Iron Deficiency in Obstetrics

NCT07083492Iron Deficiency Anemia of Pregnancy, Iron-deficiency, Restless Leg Syndrome in Pregnancy, Restless Leg Syndrome Due to Iron Deficiency Anaemia

Wuerzburg University Hospital

Observational

500

Würzburg

2022-11-15

Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428Carcinoma, Non-small-Cell Lung

DrugsDirect Anticoagulant·LMWH·DOAC·Low molecular weight heparin

Janssen Research & Development, LLC

Phase 2

520

Berlin, Cologne, Grosshandorf, Immenhausen, Würzburg

2022-11-11

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Berlin, Essen, Halle, Hamburg, Nuremberg, Tübingen, Würzburg

2022-10-25

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

Tübingen, Regensburg, Würzburg, Essen, Hamburg

2022-10-20

Active, closed

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma

NCT05535244Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1/2

Cologne, Hamburg, Würzburg

2022-10-17

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Berlin, Cologne, Hamburg, Heidelberg, Leipzig, Mainz, Würzburg

2022-10-13

Recruiting

PSMA in Gastroenterologic Tumors (GIPSMA)

NCT05547919Gastrointestinal Cancer

Wuerzburg University Hospital

Not applicable

Würzburg

2022-10-01

Active, closed

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma

NCT05371093Relapsed/Refractory Follicular Lymphoma

DrugsAxi-cel·Axicabtagene Ciloleucel·Bendamustine·Vincristine

Kite, A Gilead Company

Phase 3

231

Göttingen, Würzburg

2022-09-22

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Tübingen, Würzburg, Giessen, Kassel, Göttingen, Bonn, Dresden, Leipzig

2022-09-20

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Heidelberg, Tübingen, Erlangen, Munich, Regensburg, Würzburg, Bad Bentheim, Buxtehude

2022-09-13

Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

NCT05243797Multiple Myeloma

DrugsTeclistamab·Lenalidomide

European Myeloma Network B.V.

Phase 3

1,594

Hamburg, Heidelberg, Jena, Lübeck, München, Nuremberg, Tübingen, Würzburg

2022-09-08

Active, closed

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046Parkinson's Disease

BlueRock Therapeutics

Observational

194

Wolfach, Munich, Würzburg, Marburg, Düsseldorf, Rostock, Tübingen

2022-07-29

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Ulm, Augsburg, Regensburg, Würzburg, Marburg, Leipzig

2022-06-14

Active, closed

Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

NCT05382156Endogenous Cushing's Syndrome

DrugOsilodrostat

RECORDATI GROUP

Observational

206

Berlin, Cologne, Düsseldorf, Frankfurt, Hamburg, Munich, Oldenburg, Würzburg

2022-06-13

Active, closed

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

Würzburg, Berlin

2022-06-06

Active, closed

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775Relapsed/ Refractory Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1

Dresden, Hamburg, Heidelberg, Würzburg

2022-05-25

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548Fabry Disease

DrugsAgalsidase beta·Replagal·Venglustat·Migalastat HCl

Sanofi

Phase 3

104

Berlin, Hochheim am Main, Mainz, Würzburg

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Heidelberg, Würzburg, Buxtehude, Dresden, Kiel, Hamburg

2022-05-02

Recruiting

Lymphatic Organs and Myocardium After Myocardial Infarction

NCT05519735Myocardial Infarction, Myocardial Injury, Myocardial Inflammation

Wuerzburg University Hospital

Not applicable

Würzburg

2022-04-01

Active, closed

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD

MaaT Pharma

Phase 3

Berlin, Mannheim, Regensburg, Ulm, Würzburg

2022-03-25

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Würzburg, Mainz, Leipzig, Kiel, Berlin, Chemnitz, Essen, München

2022-03-25

Active, closed

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773Fabry Disease

DrugVenglustat

Sanofi

Phase 3

122

Munich, Würzburg

2022-03-11

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Berlin, Esslingen am Neckar, Georgsmarienhütte, Lübeck, München, Würzburg

2022-02-21

Active, closed

Setrusumab vs Placebo for Osteogenesis Imperfecta

NCT05125809Osteogenesis Imperfecta

DrugSetrusumab

Ultragenyx Pharmaceutical Inc

Phase 2/3

183

Cologne, Magdeburg, Würzburg

2022-02-21

Active, closed

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336Advanced MTAP-null Solid Tumors

DrugsAnvumetostat·Docetaxel

Amgen

Phase 1/2

329

Halle, Heidelberg, Ulm, Würzburg

2022-02-01

By invitation

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

NCT05041309Solid and Hematological Malignancies, Autoimmune Diseases

DrugsKITE-197·SPRX002·KITE-753·Tecartus

Kite, A Gilead Company

Observational

1,500

Dresden, Hamburg, Heidelberg, Mainz, München, Würzburg

2021-12-15

Active, closed

Effects of Isolated Lumbar Extension Resistance Training Alone and in Combination with General Exercise and Manual Therapy

NCT06890052Low Back Pain, Multifidus, Exercise Therapy, Diagnostic Imaging

University of Wuerzburg

Not applicable

Würzburg

2021-12-01

Active, closed

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

NCT05060016Relapsed/Refractory Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

222

Cologne, Großhansdorf, Würzburg

2021-12-01

Active, closed

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)

DrugSelumetinib

AstraZeneca

Phase 3

145

Hamburg, Tübingen, Würzburg

2021-11-19

Recruiting

Dystonia Image-based Programming of Stimulation: A Prospective, Randomized, Double-blind Crossover Trial

NCT05097001Dystonia, Deep Brain Stimulation

Wuerzburg University Hospital

Not applicable

Würzburg

2021-11-01

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

NCT04989803Relapsed and/or Refractory B-cell Lymphoma

DrugsKITE-753·KITE-363·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1/2

247

Würzburg

2021-10-27

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Ulm, Würzburg, Berlin, Braunschweig, Chemnitz, München

2021-10-04

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Chemnitz, Essen, Kerpener, Koelner Platz 1, Leipzig, Rostock, Würzburg

2021-09-20

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Aachen, Dresden, Hamburg, Würzburg

2021-09-16

Active, closed

Long-Term Follow-up of Subjects Who Were Treated With ST-920

NCT05039866Fabry Disease, Fabry Disease, Cardiac Variant

Sangamo Therapeutics

Observational

Würzburg

2021-08-16

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Munich, Würzburg, Frankfurt am Main, Hanover, Cologne, Essen, Münster, Dresden

2021-08-16

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor

DrugBelzutifan

Merck Sharp & Dohme LLC

Phase 2

355

Freiburg im Breisgau, München, Würzburg, Düsseldorf, Berlin

2021-08-12

Recruiting

A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

NCT04201210HbS Disease, Hemoglobin S Disease, Sickle Cell Anemia, Sickle Cell Disorders

University of Regensburg

Phase 2

212

Aachen, Berlin, Düsseldorf, Frankfurt, Heidelberg, Regensburg, Tübingen, Würzburg

2021-06-30

Active, closed

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157Prostatic Neoplasms

DrugsARDT·Illuccix·Lu-PSMA

Novartis Pharmaceuticals

Phase 3

1,140

Würzburg, Cologne, Essen, München, Münster, Rostock

2021-06-09

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 1/2

1,109

Ulm, Dresden, Essen, Frankfurt, Würzburg

2021-05-27

Active, closed

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

NCT04835805Melanoma

DrugsBelvarafenib·Cobimetinib·Nivolumab

Genentech, Inc.

Phase 1

Berlin, Hamburg, Mannheim, Tübingen, Würzburg

2021-05-13

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

Berlin, Essen, Goettigen, Heidelberg, Jena, Würzburg

2021-05-06

Active, closed

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344Muscle-invasive Bladder Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

761

Düsseldorf, Halle, Herne, Tübingen, Ulm, Würzburg

2021-05-03

Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

NCT04883905Acute Hepatic Porphyria

Alnylam Pharmaceuticals

Observational

150

Berlin, Chemnitz, Würzburg

2021-04-26

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Freiburg im Breisgau, Tübingen, Regensburg, Würzburg, Herne, Münster, Dresden, Halle

2021-04-21

Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

NCT04663750Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage

King's College Hospital NHS Trust

Phase 3

210

Bonn, Hamburg, Ludwigshafen, München, Münster, Sulzbach, Ulm, Würzburg

2021-04-16

Active, closed

Plasmafit® Revision Structan® Hip Endoprosthesis Cup

NCT04255966Osteolysis, Arthroplasty Complications, Instability of Prosthetic Joint, Degenerative Osteoarthritis

Aesculap AG

Observational

Würzburg, Braunschweig, Bonn, Homburg

2021-04-12

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg

2021-04-08

Active, closed

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04732871Respiratory Syncytial Virus Infections

GlaxoSmithKline

Phase 3

1,720

Essen, Goch, Hamburg, Mainz, München, Wallerfing, Würzburg

2021-02-15

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Berlin, Heidelberg, Münster, Würzburg

2021-02-01

Recruiting

Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

NCT04761120Mitral Regurgitation, Tricuspid Regurgitation, Valvular Heart Disease

Abbott Medical Devices

Observational

550

Passau, Würzburg, Bremen, Dresden, Jena

2021-02-01

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Cologne, Essen, Kiel, Würzburg

2021-01-13

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

München, Würzburg

2020-12-28

Active, closed

Atrasentan in Patients With IgA Nephropathy

NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy

DrugsAtrasentan·Zigakibart

Novartis Pharmaceuticals

Phase 3

404

Cloppenburg, Hanover, Hoyerswerda, Jena, Villingen-Schwenningen, Würzburg

2020-12-11

Active, closed

AMEND-CRT: Mechanical Dyssynchrony as Selection Criterion for CRT

NCT04225520Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular

Universitaire Ziekenhuizen KU Leuven

Not applicable

500

Cologne, Rostock, Würzburg

2020-12-10

Active, closed

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

NCT04725474Solid Tumor, Adult

DrugsVisugromab·Nivolumab

CatalYm GmbH

Phase 1/2

199

Essen, Frankfurt am Main, Würzburg

2020-12-09

Recruiting

COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life

NCT04679584COVID-19

University Hospital Schleswig-Holstein

Observational

2,000

Würzburg, Kiel, Berlin

2020-11-16

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Berlin, Düsseldorf, Essen, Hamburg, Heidelberg, Würzburg

2020-11-03

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Ulm, Würzburg

2020-10-02

Active, closed

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Multiple Myeloma

DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone

GlaxoSmithKline

Phase 3

302

Mainz, Tübingen, Würzburg

2020-10-01

Active, closed

Burden of Disease and Functional Impairment in XLH

NCT04946409X Linked Hypophosphatemia

Wuerzburg University Hospital

Observational

Würzburg

2020-10-01

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Heidelberg, Leipzig, Tübingen, Würzburg

2020-09-17

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

NCT04673955Metastatic Colorectal Carcinoma

DrugsEncorafenib·Erbitux·Cetuximab

Pierre Fabre Pharma GmbH

Observational

500

Offenburg, Ulm, Augsburg, Donauwörth, Erlangen, München, Würzburg, Aschaffenburg

2020-09-03

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

125

Berlin, Düsseldorf, Essen, Hamburg, Heidelberg, Würzburg

2020-08-25

Active, closed

A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

NCT04429087Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

DrugObrixtamig

Boehringer Ingelheim

Phase 1

306

Cologne, Dresden, Würzburg

2020-07-29

Recruiting

Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)

NCT05865054Giant Cell Arteritis

University of Pennsylvania

Observational

400

Würzburg

2020-07-29

Active, closed

Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

NCT04309409Malignant Melanoma Stage II

DrugsOpdivo·Nivolumab

University Hospital, Essen

Phase 3

374

Würzburg, Rostock, Augsburg, Bochum, Dortmund, Dresden, Erfurt, Essen

2020-07-01

Active, closed

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553Crohn's Disease

DrugMirikizumab

Eli Lilly and Company

Phase 3

996

Pforzheim, Würzburg, Frankfurt am Main, Lauterbach, Hanover, Bottrop, Wipperfürth, Leipzig

2020-06-22

Active, closed

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827Multiple Myeloma

DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

419

Cologne, Dresden, Hamburg, Leipzig, Tübingen, Würzburg

2020-06-12

Active, closed

Adipositas Care & Health Therapy

NCT04768127Patients After Metabolic-bariatric Surgery, Obesity, Morbid

Wuerzburg University Hospital

Not applicable

586

Gräfelfing, Memmingen, München, Nuremberg, Offenbach, Passau, Würzburg

2020-05-15

Recruiting

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

NCT03993262Autoimmune Encephalitis

DrugBortezomib

Jena University Hospital

Phase 2

München, Würzburg, Jena, Hanover, Berlin, Bochum, Düsseldorf, Erlangen

2020-05-13

Active, closed

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer

ImCheck Therapeutics, an Ipsen company

Phase 1/2

293

Dresden, Würzburg

2020-03-05

Active, closed

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

NCT04108195Multiple Myeloma

DrugsTalquetamab·Darzalex·Teclistamab·Pomalidomide

Janssen Research & Development, LLC

Phase 1

290

Freiburg im Breisgau, Hamburg, Heidelberg, Würzburg

2020-02-21

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

München, Würzburg, Hanover, Essen, Mainz, Magdeburg, Berlin, Hamburg

2020-02-11

Active, closed

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

NCT03947619ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

Abiomed Inc.

Not applicable

527

Würzburg, Düsseldorf, Essen, Trier, Dresden, Jena, Marburg, Zwickau

2019-12-12

Active, closed

SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.

NCT04053088Cardiovascular Diseases

Institut für Pharmakologie und Präventive Medizin

Observational

500

Nuremberg, Passau, Würzburg, Frankfurt am Main, Oldenburg, Aachen, Bad Rothenfelde, Bochum

2019-12-12

Active, closed

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

655

Frankfurt am Main, Leipzig, Essen, Göttingen, Heidelberg, Münster, Würzburg

2019-11-26

Active, closed

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

NCT03888105B-cell Non-Hodgkin Lymphoma (B-NHL)

DrugOdronextamab

Regeneron Pharmaceuticals

Phase 2

515

Mutlangen, Halle, Würzburg

2019-11-13

Active, closed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 2

208

Hamburg, Würzburg

2019-11-07

Recruiting

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

NCT04032470Essential Tremor

Boston Scientific Corporation

Observational

500

Cologne, Düsseldorf, Essen, Kiel, Marburg, Oldenburg, Würzburg

2019-10-23

Active, closed

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414Multiple Myeloma

DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib

Celgene

Phase 1/2

424

Freiburg im Breisgau, Hamburg, Heidelberg, München, Würzburg

2019-09-30

Active, closed

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma

DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed

Genmab

Phase 1/2

350

Heidelberg, Ludwigshafen, Mainz, Mannheim, Würzburg

2019-09-17

Active, closed

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

DrugXeomin

Merz Pharmaceuticals GmbH

Phase 3

603

Aachen, Berlin, Bonn, Düsseldorf, Hamburg, Wiesbaden, Würzburg

2019-09-16

Active, closed

LITMUS Imaging Study

NCT05479721NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver

University of Oxford

Observational

450

Mainz, Würzburg

2019-09-04

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Stuttgart, Tübingen, Erlangen, Munich, Würzburg, Bonn, Dresden, Magdeburg

2019-07-24

Active, closed

IMPEDE and IMPEDE-FX Embolization Plug Registry

NCT04044443Peripheral Vascular Embolization

Shape Memory Medical, Inc.

Observational

108

Dresden, Heidelberg, Kiel, Leipzig, München, Nuremberg, Stuttgart, Würzburg

2019-07-09

Recruiting

Radiotherapy of Head and Neck Cancer With SIB

NCT06831903Quality of Life (QOL), Head and Neck Cancer, Radiotherapy Side Effect, Radiotherapy, Conformal (IMRT)

Wuerzburg University Hospital

Observational

750

Würzburg

2019-05-21

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer

DrugsAnzu-cel·Opdivo·Nivolumab

Immatics US, Inc.

Phase 1/2

375

Heidelberg, Munich, Würzburg, Bonn, Mainz, Dresden, Berlin, Hamburg

2019-05-14

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Berlin, Frankfurt am Main, Homburg, Leipzig, Mainz, Würzburg

2019-03-28

Recruiting

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

NCT03664609Parkinson Disease, Essential Tremor, Dystonia

Boston Scientific Corporation

Observational

5,000

Cologne, Düsseldorf, Jena, Lübeck, Würzburg

2019-03-12

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab

Acerta Pharma BV

Phase 3

984

Paderborn, Würzburg

2019-02-25

Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT03761108Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

387

Essen, Mainz, Würzburg

2019-01-23

Active, closed

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

NCT03711032High-risk Non-muscle Invasive Bladder Cancer

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,397

Munich, Weiden in Der Oberpfalz, Würzburg, Trier, Jena

2018-12-24

Active, closed

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease

NCT03737214Fabry Disease

Idorsia Pharmaceuticals Ltd.

Phase 3

107

Berlin, Höchheim, Müllheim, Würzburg

2018-12-18

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Ravensburg, Munich, Würzburg, Cottbus, Frankfurt am Main, Georgsmarienhütte, Hanover, Essen

2018-12-07

Recruiting

Pulmonary Hemodynamics During Exercise - Research Network

NCT03954574Pulmonary Circulation Diseases

Medical University of Graz

Observational

1,500

Cologne, Giessen, Greifswald, Heidelberg, Würzburg

2018-12-01

Active, closed

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

NCT03853616Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent

DrugMB-CART19.1

Miltenyi Biomedicine GmbH

Phase 1

Berlin, Erlangen, Göttingen, Munich, Münster, Tübingen, Würzburg

2018-11-26

Active, closed

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

NCT03235245Unresectable Stage III Melanoma, Stage IV Melanoma

DrugsBinimetinib·Encorafenib·Ipilimumab·Nivolumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

271

Heidelberg, Mainz, Würzburg

2018-10-30

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg

2018-10-22

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

DrugCabozantinib

Exelixis

Phase 3

187

Tübingen, Würzburg, Marburg, Hanover, Dresden, Magdeburg, Aachen, Bonn

2018-10-05

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Mannheim, Tübingen, Munich, Nuremberg, Würzburg, Buxtehude, Hanover, Essen

2018-09-12

Recruiting

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma

DrugsMitotane·Cis-platinum·CDDP·Etoposide

M.D. Anderson Cancer Center

Phase 3

240

Munich, Würzburg

2018-08-20

Active, closed

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198Cushing Syndrome

DrugRelacorilant

Corcept Therapeutics

Phase 2

125

Munich, Würzburg

2018-05-07

Active, closed

Pyruvate Kinase Deficiency Global Longitudinal Registry

NCT03481738Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc.

Observational

500

Berlin, Bielefeld, Heidelberg, Munich, Würzburg

2018-04-23

Active, closed

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940Small Cell Lung Carcinoma

DrugsTarlatamab·Pembrolizumab

Amgen

Phase 1

269

Würzburg

2017-12-26

Recruiting

Registry for Hypoparathyroidism Wuerzburg

NCT05585593Comorbidities and Coexisting Conditions, Morality, Hypocalcemia, Hypercalcemia

University of Wuerzburg

Observational

300

Würzburg

2017-10-18

Active, closed

The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients

NCT03188796Critical Illness, Vitamin D Deficiency, Covid19

DrugCholecalciferol

Medical University of Graz

Phase 3

2,400

Würzburg

2017-10-10

Recruiting

Taper Or Abrupt Steroid Stop: TOASSTtrial

NCT03153527Inflammatory Disorder, Autoimmune

DrugPrednisone

University Hospital, Basel, Switzerland

Phase 4

530

Frankfurt, Würzburg

2017-05-31

Active, closed

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor

DrugSelpercatinib

Eli Lilly and Company

Phase 1/2

857

Würzburg, Cologne

2017-05-02

Active, closed

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272Solid Tumor

DrugsNab-paclitaxel·Gemcitabine·Cisplatin

Eli Lilly and Company

Phase 1

223

Würzburg, Berlin

2016-11-21

Active, closed

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

NCT02773030Multiple Myeloma

DrugsIberdomide·Darzalex·Velcade·Carfilzomib

Celgene

Phase 1/2

466

Dresden, Düsseldorf, Hamburg, Heidelberg, Tübingen, Würzburg

2016-10-14

Active, closed

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

NCT02584933ALK Positive Malignancies

DrugCeritinib

Novartis Pharmaceuticals

Phase 4

233

Regensburg, Cologne, Essen, Heidelberg, Würzburg

2015-12-11

Recruiting

CAR-T Long Term Follow Up (LTFU) Study

NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program

Novartis Pharmaceuticals

Phase 3

1,105

Munich, Regensburg, Würzburg, Frankfurt am Main, Cologne, Leipzig, Berlin, Hamburg

2015-11-02

Recruiting

The German ADPKD Tolvaptan Treatment Registry

NCT02497521ADPKD (Autosomal Dominant Polycystic Kidney Disease)

University of Cologne

Observational

2,000

Müllheim, Würzburg, Hanover, Cologne, Nettetal, Leipzig, Lübeck, Berlin

2015-11

Recruiting

The European NAFLD Registry

NCT04442334NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver

Newcastle University

Observational

10,000

Aachen, Berlin, Freiburg im Breisgau, Mainz, Würzburg

2015-05-01

Active, closed

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer

NCT01704586Differentiated Thyroid Carcinoma

University of Wuerzburg

Not applicable

340

Essen, Würzburg

2015-05

By invitation

Registry of Patients With Hypophosphatasia

NCT02306720Hypophosphatasia (HPP)

Alexion Pharmaceuticals, Inc.

Observational

1,571

Bad Reichenhall, Würzburg, Bochum, Düsseldorf, Dresden, Berlin, Cologne, Giessen

2015-01-20

Active, closed

Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas

NCT04917757Adrenal Incidentaloma

Wuerzburg University Hospital

Observational

3,656

Würzburg

2015-01-01

Recruiting

Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

NCT03256240Crohn's Disease

Weill Medical College of Cornell University

Not applicable

600

Würzburg, Berlin, Mannheim

2014-03-12

Active, closed

Evaluation of Side Effects of Mitotane

NCT00568139Adrenocortical Carcinoma

University of Wuerzburg

Observational

400

Würzburg

2008-01

Active, closed

Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

NCT00457587Adrenocortical Carcinoma, Cushing's Syndrome

University of Wuerzburg

Observational

150

Würzburg

2005-09

Recruiting

German Adrenocortical Carcinoma Registry

NCT00453674Adrenocortical Carcinoma

University of Wuerzburg

Observational

1,000

Würzburg

2003-01-01

Recruiting

Adrenal Tumors - Pathogenesis and Therapy

NCT00669266Adrenal Tumors, Adrenocortical Carcinoma, Cushing Syndrome, Conn Syndrome

University of Wuerzburg

Observational

500

Würzburg

2002-09

Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

NCT00196742Fabry Disease

Genzyme, a Sanofi Company

Observational

9,000

Berlin, Giessen, Münster, Würzburg

2001-07-31

Recruiting

Evaluation of HEArt invoLvement in Patients With FABRY Disease

NCT03362164Rare Diseases, Fabry Disease, Fabry Disease, Cardiac Variant, Hypertrophic Cardiomyopathy

Wuerzburg University Hospital

Observational

650

Würzburg

2001-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 October 2026. https://priyalifescience.com/clinical-trials-germany/city/w-rzburg

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 20 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 295 of those studies with a site in Würzburg.

How many clinical trials are recruiting in Würzburg?

147 of the 295 studies on this page are recruiting new participants as of the 20 Oct 2026, 03:18 UTC sync. A further 10 have not yet opened recruitment, 131 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Würzburg), 295 studies
Phase	Studies	Recruiting	Share
Phase 3	100	31	33.9%
Observational	61	40	20.7%
Phase 2	42	24	14.2%
Not applicable	31	21	10.5%
Phase 1	25	9	8.5%
Phase 1/2	24	15	8.1%
Phase 2/3	8	5	2.7%
Phase 4	4	2	1.4%

Most active sponsors

Lead sponsors with the most studies (Würzburg)
Lead sponsor	Studies	Recruiting
Wuerzburg University Hospital	22	18
AstraZeneca	16	10
Novartis Pharmaceuticals	15	4
Janssen Research & Development, LLC	14	4
Amgen	13	3
AbbVie	9	4
Merck Sharp & Dohme LLC	7	2
University of Wuerzburg	7	3
Alexion Pharmaceuticals, Inc.	6	0
argenx	6	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.